Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Novartis logo

Novartis

Status and phase

Completed
Phase 3

Conditions

Hypertension

Treatments

Drug: Placebo
Drug: Aliskiren 300 mg
Drug: Aliskiren 75 mg
Drug: Aliskiren 150 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT00706134
CSPP100A2405

Details and patient eligibility

About

This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.

Enrollment

756 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and female outpatients 65 years of age and older.
  • Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
  • At the randomization visit patients must have an office msSBP greater than or equal to 150 mmHg and < 180 mmHg (msDBP <110 mmHg) with a less than or equal to 15 mmHg difference during the last two visits of the single blind run-in period.

Exclusion criteria

  • Severe hypertension [Office msDBP ≥110 mmHg and/or mean sitting systolic blood pressure (msSBP) ≥ 180 mmHg].
  • History or evidence of a secondary form of hypertension.
  • Known Keith-Wagener grade III or IV hypertensive retinopathy.
  • History of hypertensive encephalopathy or cerebrovascular accident, including a history of transient ischemic cerebral attack (TIA).
  • Current diagnosis of heart failure (NYHA Class II-IV).
  • History of myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).
  • Current angina pectoris requiring pharmacological therapy other than nitrates.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Trial design

756 participants in 4 patient groups, including a placebo group

Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
Aliskiren 75 mg
Experimental group
Treatment:
Drug: Aliskiren 75 mg
Aliskiren 150 mg
Experimental group
Treatment:
Drug: Aliskiren 150 mg
Aliskiren 300 mg
Experimental group
Treatment:
Drug: Aliskiren 300 mg

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems